MARIA
Maria is a diabetic in Phoenix, Arizona. In 2018, her insurance stopped covering insulin at the price her pharmacy charged. She stretched a thirty-day supply to sixty days. In August of that year she was hospitalized with diabetic ketoacidosis — a preventable emergency caused by insufficient insulin. Her hospital bill for the three-day stay was $47,000. The insulin she had been rationing costs approximately $3 to manufacture. It sells for $30 in Canada. It sells for up to $300 in the United States.
The difference between $30 and $300 is not production cost, transportation, or research amortization. Insulin was developed in 1921. The patent was sold to the University of Toronto for $1 by its inventors, who believed no one should profit from a medicine people require to live. The difference is what a market, shaped by decades of lobbying-influenced legislation, can extract from people who will die without the drug.
Maria's story is not an anecdote about one person's bad luck. It is a precise illustration of a system that functions exactly as designed — for the people who designed it.
SOURCE: Kaiser Family Foundation (2022). Insulin Costs and Affordability. | Congressional Budget Office (2022). Prices for Brand-Name Drugs. | Banting, F. & Best, C. (1921). University of Toronto patent records.
WHAT REGULATORY CAPTURE ACTUALLY MEANS
Regulatory capture is not corruption in the traditional sense of envelopes of cash. It is the structural process by which the industries being regulated come to staff, fund, and direct the agencies regulating them. The revolving door between pharmaceutical companies and the FDA is documented in employment records that are public: senior FDA officials moving to pharmaceutical industry positions, pharmaceutical executives moving to FDA advisory positions, and the salaries available in the industry creating a structural incentive for FDA staff to reach conclusions acceptable to potential future employers.
The result is a healthcare system that produces worse outcomes than peer nations spending significantly less per capita while generating the highest pharmaceutical profits in the world. This is not market failure. It is market success — for the market that was actually built, which is not a market for health but a market for the management of illness at maximum sustainable cost.
SOURCE: Angell, M. (2004). The Truth About the Drug Companies. Random House. | PLOS Medicine (2018). Revolving Door study of FDA-pharmaceutical industry personnel movement.
FIFTY YEARS AND 50,000 DEATHS: THE TRANS FAT RECORD
The FDA knew by the 1950s that partially hydrogenated oils — trans fats — produced health effects worth investigating. Research throughout the 1990s established cardiovascular harm with increasing certainty. Dariush Mozaffarian's landmark study in the New England Journal of Medicine in 2006 estimated that trans fat consumption was causing between 72,000 and 228,000 coronary heart disease events per year in the United States, with approximately 50,000 fatal.
The FDA banned partially hydrogenated oils in 2015. Fifty years elapsed between established knowledge of harm and regulatory action. During that interval, conservative estimates of preventable deaths run into the hundreds of thousands. The food industry, which had invested in trans fat infrastructure, lobbied against regulation successfully for five decades. The people who died were not killed by ignorance. They were killed by a regulatory system that chose industry interest over public health for half a century and called the arrangement consumer protection.
SOURCE: Mozaffarian, D. et al. (2006). Trans Fatty Acids and Cardiovascular Disease. New England Journal of Medicine, 354(15), 1601-1613. | FDA Final Determination on Partially Hydrogenated Oils (2015).
THE OPIOID CRISIS: MANUFACTURED ADDICTION AT SCALE
Purdue Pharma began marketing OxyContin in 1996 on the basis of a claim that extended-release opioids had a low addiction potential. The company's own research did not support this claim. Purdue paid physicians to speak at conferences promoting the drug, funded patient advocacy organizations, and trained a sales force to minimize addiction concerns when raised by healthcare providers. The DEA and FDA received documented reports of diversion and addiction and delayed substantive action for years.
By 2021, opioid overdoses were killing over 80,000 Americans annually. The Sackler family, which owned Purdue Pharma, extracted approximately $10 billion from the company before its bankruptcy. The bankruptcy settlement — negotiated after years of litigation — allowed family members to avoid criminal prosecution in exchange for payment. This is the accountability the regulatory system provides for manufactured addiction at scale that killed more Americans than the Vietnam War: civil settlement, structured bankruptcy, and personal legal immunity.
SOURCE: Keefe, P.R. (2021). Empire of Pain: The Secret History of the Sackler Dynasty. Doubleday. | CDC Opioid Overdose Data (2022). | Purdue Pharma bankruptcy court records (2021).
THE MEDICARE PROHIBITION AND THE LOBBYING ARITHMETIC
The Medicare Modernization Act of 2003 explicitly prohibited Medicare — the single largest purchaser of pharmaceuticals in the United States — from negotiating drug prices. No other large-volume purchaser in any other industry is legally prohibited from negotiating price. The Veterans Administration negotiates pharmaceutical prices and pays approximately 40% less than Medicare for the same drugs. The Congressional Budget Office has estimated that allowing Medicare price negotiation would save hundreds of billions of dollars over a decade.
The prohibition was written into law by legislators who received pharmaceutical industry campaign contributions. OpenSecrets.org, using publicly available Federal Election Commission records, has documented the correlation between pharmaceutical PAC contributions and votes against Medicare price negotiation over multiple congressional cycles. This is arithmetic performed on public records. The conclusion it produces does not require inference.
SOURCE: Congressional Budget Office (2019). Incorporating the Effects of Proposals to Modify Drug Rebates. | OpenSecrets.org pharmaceutical industry contribution data (2000-2024). | Medicare Prescription Drug, Improvement, and Modernization Act (2003), Section 1860D-11(i).
THREE CHANGES THAT WOULD TRANSFORM THE SYSTEM
First: repeal the Medicare price negotiation prohibition. This single legislative change — requiring only organized political will sufficient to outweigh pharmaceutical lobbying — would immediately reduce drug costs for the largest buyer in the country and create price pressure throughout the market. The Inflation Reduction Act of 2022 began this process for ten drugs. The prohibition was never justified by anything other than lobbying capacity.
Second: restore standard bankruptcy protections to medical debt. Medical debt is a leading cause of personal bankruptcy in the United States. It is the only category of debt that typically accrues without the debtor's advance knowledge of the amount — you do not know what an emergency room visit will cost before you are treated. Applying standard bankruptcy protections would not eliminate medical debt. It would eliminate the mechanism by which medical debt becomes a permanent financial condition for people who had the misfortune to become sick.
Third: mandate transparent hospital billing. The chargemaster system — by which hospitals assign list prices to procedures that bear no documented relationship to actual costs, then negotiate downward depending on the payer's leverage — is the mechanism that produces $47,000 bills for three-day stays and $200 aspirin. Transparency requirements would not fix the underlying incentive structure but would make the mechanism visible enough to generate the political pressure required to address it.
None of these requires a fundamental restructuring of the healthcare economy. All of them require defeating the lobbying investment of industries that profit from the current arrangement. That is achievable. Maria's situation is not inevitable. It is a policy choice that can be unmade.